VCEL
Vericel Corporation · Healthcare
Insiders sold $7.2M of Vericel Corporation in the last 12 months and bought none
VCEL over the last year
VCEL after insider buys
3 months after each buy, from the first price a copier could get.
No buys have 3 months of prices yet. A record shows here at 3.
Every filing
110 insider filings since 2016, newest first
Kevin F Mclaughlin · Director
Michael Halpin · Chief Operating Officer
Jonathan Siegal · Principal Accounting Officer
Jonathan Siegal · Principal Accounting Officer
Joseph Anthony Mara Jr · Chief Financial Officer
Jonathan Mark Hopper · Chief Medical Officer
Sean C. Flynn · Chief Legal Officer
Michael Halpin · Chief Operating Officer
Sean C. Flynn · Chief Legal Officer
Jonathan Mark Hopper · Chief Medical Officer
Kevin F Mclaughlin · Director
Paul K Wotton · Director
Joseph Anthony Mara Jr · CFO
Jonathan Siegal · Principal Accounting Officer
Jonathan Mark Hopper · Chief Medical Officer
Heidi Hagen · Director
Sean C. Flynn · General Counsel
Michael Halpin · COO
Kevin F Mclaughlin · Director
Michael Halpin · COO
Jonathan Mark Hopper · Chief Medical Officer
Paul K Wotton · Director
Robert L Md Zerbe · Director
Kevin F Mclaughlin · Director
Dominick Colangelo · President and CEO
Robert L Md Zerbe · Director
Dominick Colangelo · President and CEO
Steven C Gilman · Director
Steven C Gilman · Director
Steven C Gilman · Director
Dominick Colangelo · President and CEO
Jonathan Mark Hopper · Chief Medical Officer
Steven C Gilman · Director
Dominick Colangelo · President and CEO
Kevin F Mclaughlin · Director
Dominick Colangelo · President and CEO
Sean C. Flynn · General Counsel
Joseph Anthony Mara Jr · CFO
Sean C. Flynn · General Counsel
Dominick Colangelo · President and CEO
Jonathan Mark Hopper · Chief Medical Officer
Dominick Colangelo · President and CEO
Dominick Colangelo · President and CEO
Robert L Md Zerbe · Director
Dominick Colangelo · President and CEO
Sean C. Flynn · SVP and General Counsel
Michael Halpin · COO
Jonathan Siegal · Principal Accounting Officer
Robert L Md Zerbe · Director
Dominick Colangelo · President and CEO
About Vericel Corporation
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Burlington, Massachusetts.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.